AtaiBeckley (ATAI) EBIT Margin (2021 - 2026)
AtaiBeckley (ATAI) posted quarterly EBIT Margin of 3239.1% for Q1 2026, down 192913.0% year-over-year from N/an in Q1 2025, and down 147.27% quarter-over-quarter from 1309.97% in Q1 2025.
Powered by 
Analysis
AtaiBeckley (ATAI) EBIT Margin (2021 - 2026) Analysis & Trends
AtaiBeckley has reported EBIT Margin for 5 years, with the latest figure at 3796.53% in Q3 2025.
- Quarterly EBIT Margin rose 5270847.0% year-over-year to 3796.53% in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 3438.02% (up 2857920.0% YoY) and the FY2024 annual result came in at 33341.23%, up 661768.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 3239.1%, down from 1309.97% in the prior quarter.
- The five-year high for EBIT Margin was 1309.97% in Q1 2025, with the low at 3239.1% in Q1 2026.
- A 5-year average of 60266.07% and a median of 20219.77% in 2021 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2022 and 2023: EBIT Margin sank 14755410 bps in 2022, then surged 12925216 bps in 2023.
- Over 5 years, EBIT Margin stood at 19641.3% in 2021, then tumbled by 403 bps to 98855.26% in 2022, then sank by 89 bps to 186450.0% in 2023, then tumbled by 35 bps to 252208.33% in 2024, then surged by 98 bps to 3796.53% in 2025.
- According to Business Quant data, EBIT Margin over the past three periods registered 3796.53%, 3515.02%, and 1309.97% for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 19.75% |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 10 | AtaiBeckley | 1.61 Bn | 1.61 Bn | - | -3,796.53% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,590.43% |
| Mar 31, 2026 | -3,239.10% |
| Sep 30, 2025 | -3,796.53% |
| Jun 30, 2025 | -3,515.02% |
| Jun 30, 2025 | -3,515.02% |
| Mar 31, 2025 | -1,309.97% |
| Mar 31, 2025 | -1,309.97% |
| Dec 31, 2024 | -252,208.33% |
| Sep 30, 2024 | -56,505.00% |
| Jun 30, 2024 | -9,424.54% |
| Dec 31, 2023 | -186,450.00% |
| Sep 30, 2023 | -30,843.68% |
| Jun 30, 2023 | -18,524.42% |
| Mar 31, 2023 | -89,767.57% |
| Dec 31, 2022 | -98,855.26% |
| Sep 30, 2022 | -160,095.83% |
| Jun 30, 2022 | -20,798.24% |
| Dec 31, 2021 | -19,641.30% |
| Sep 30, 2021 | -12,541.73% |
| Mar 31, 2021 | 20.37% |